Exagen Inc. Common Stock (XGN)
Exagen Inc. (XGN) is a biotechnology company focused on developing and commercializing diagnostic tests to improve the management of autoimmune diseases. The company specializes in innovative testing solutions that aid in diagnosing conditions such as lupus and rheumatoid arthritis, aiming to enhance patient outcomes through precise and early detection.
Company News
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, w...
BTIG has decided to maintain its Buy rating of Exagen (NASDAQ:XGN) and lower its price target from $6.00 to $5.00. Shares of Exagen are trading down 3.91% over the last 24 hours, at $2.21 per share. A move to $5.00 would account for a 126.24% increase from the current share price. About Exagen Exagen Inc is a commercial-stage diagnostics company ...
XGN earnings call for the period ending June 30, 2022.